Symposium 9: The impact of metabolic surgery on diabetes and fatty liver
DOI:
https://doi.org/10.47196/diab.v54i3Sup.307Keywords:
bariatric surgery, liver diseaseAbstract
Symposium 9: Hepatic involvement in diabetes: beyond the liver
The impact of metabolic surgery on diabetes and fatty liver
The Second Diabetes Surgery Summit (DSS II) formally recognized gastrointestinal surgery, also known as Metabolic Surgery (MC), as treatment for Type 2 Diabetes (T2D) patients with obesity. This treatment has been added to the Standards of Medical Care in Diabetes from the ADA in 2017.
Studies show that performing surgeries on the digestive system can have beneficial consequences on glucose's homeostasis, regardless of weight loss. Surgery improves glucose's levels on blood with greater effectiveness than any lifestyle change and/or medication, and produces remission of T2D in most patients, especially if candidates to MC are carefully selected.
References
- Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016; 39: 861–77
- Lee Y, et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019 May;17(6):1040-1060.e11.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
